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Abstract To efficiently combat solid tumours, endoge-
nously or adoptively transferred cytotoxic T cells and
natural killer (NK) cells, need to leave the vasculature,
traverse the interstitium and ultimately infiltrate the tumour
mass. During this locomotion and migration in the three
dimensional environment many obstacles need to be
overcome, one of which is the possible impediment of the
extracellular matrix. The first and obvious one is the sub-
endothelial basement membrane but the infiltrating cells
will also meet other, both loose and tight, matrix structures
that need to be overridden. Matrix metalloproteinases
(MMPs) are believed to be one of the most important
endoprotease families, with more than 25 members, which
together have function on all known matrix components.
This review summarizes what is known on synthesis,
expression patterns and regulation of MMPs in cytotoxic
lymphocytes and their possible role in the process of
tumour infiltration. We also discuss different functions of
MMPs as well as the possible use of other lymphocyte
proteases for matrix degradation.
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Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are zinc-dependent
enzymes of great importance for extracellular matrix
(ECM) degradation and basal membrane (BM) penetration
by lymphocytes [1, 2]. This review summarizes the current
data available regarding the reported repertoire of MMPs,
their regulation in cytotoxic lymphocytes, T cells and
natural killer (NK) cells as well as their impact on tumour
infiltration and immunomodulation.
There are at least 25 described MMP members, all
encoded by different genes. While there is substantial
overlap in the MMP family with respect to specificity, they
can be divided into four subgroups, i.e. interstitial collage-
nases (MMP-1, -8, -13 and MMP-18), gelatinases (MMP-2
and MMP-9), stromelysins (MMP-3, -10, -11, -7, -26 and
MMP-27) and the membrane type MMPs (MT-MMPs)
designated MT1-4 (MMP-14-17), MT5- (MMP-24) and
MT6-MMP (MMP-25). The membrane bound MMPs are
attached to the cell surface either through a single pass
C-terminal transmembrane domain (as for MT1-, MT2-,
MT3-, and MT5-MMP) or a glycosyl phosphatidylinosi-
tol (GPI) anchor (MT4- and MT6-MMP).
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Expression and Regulation of MMPs in NK Cells
A variety of MMP members, namely MMP-1, -2, -9, -13,
MT1-, MT2-, MT3- and MT6-MMP has been described to be
expressed in freshly isolated human NK cells [3–6]. In
addition, MMP-3, -7, -10 and -11 have been found to be
expressed in rodent NK cells [7–10]. Detection of the
various MMPs in NK cells has mainly been done by mRNA
expression analysis, i.e. RT-PCR, while MMP-1, -2, -9,
MT1- and MT2-MMP have been verified also on the protein
level by gelatine zymography and Western blot [3–5, 7].
Even though many MMPs have been detected in NK cells,
lessisknown about their regulation. NK cells has been shown
to up-regulate their expression of MMP-2 upon cross-linking
of the activating receptor 2B4 [11] and the prostaglandin
PGE2 enhances NK cell secretion of MMP-1 and MMP-3
and can thereby facilitates their migration through Matrigel
filters [9]. The chemokine CXCL12 has further been found
to enhance human NK cell invasion into type I collagen, as
described to be in an MMP-1-dependent manner [4]a n d
stimulation of human NK cells by the cytokine IL-18
increased their migration through Matrigel as well as their
expression of MMP-2, -9 and MT1-MMP [5]. In human NK
cells the effect of IL-2 is more difficult to study than in T
cells, due to being ubiquous for NK cell culture. Using the
IL-2-independent NK cell line YT to study the effects of IL-
2 on NK cells we found an early stimulatory effect on MMP-
9 secretion, and an enhanced migration through Matrigel.
However, prolonged IL-2 stimulation resulted in reduced
Matrigel invasion and a significant decrease in the expres-
sion of several MMPs. Thus, these in vitro data indicate a
down-regulation of MMPs in response to continued cytokine
stimulation. This may, in part, explain the reduced tumour
infiltration by adoptively transferred NK and CD8+ T cells
stimulated with IL-2 for 8–10 days compared to those
stimulated with IL-2 for only 4–6d a y s[ 12]. Similarly, a
prolonged culture of mouse T cells in IL-2 demonstrated a
decreased anti-tumour activity in vivo [13].
Expression and Regulation of MMPs in T Cells
To date more is known about MMP regulation in T cells
compared to NK cells. However, basically all publications
in T cells concern MMP-2 and MMP-9 expression, where
the latter is constitutively produced and MMP-2 is
generated in response to antigen or cytokine stimulation
[14–18]. Although, MMP-28, MT2-, MT3- and MT5-MMP
have also been found to be expressed in T cell populations
of ≥97% purity, by RT-PCR [19]. It could well be that the
repertoire of MMPs in T cells is even larger, but has so far
not been clearly reported on. For reference, in B cells, so far
MMP-3, MMP-9, MMP-26 and MMP-27 have been
reported to be expressed [19–21], but also for this lineage
of lymphocytes MMPs have not yet been thoroughly
studied. To our knowledge expression of MMPs has not
been verified in regulatory T cells (Tregs). However, a
Treg-mediated inhibitory effect on MMP activity and
adverse cardiac remodeling has been found using a murine
model of myocardial infarction [22].
A vast variety of factors have been described to affect
gelatinase production by T cells. MMP-2 is up-regulated
throughVCAM-1-dependentadhesiontoendothelialcells[15]
while MMP-9 is up-regulated by vasoactive intestinal peptide
(VIP), the chemokines RANTES and MIP-1α, the prosta-
glandin PGE2, the leukotriene B4, TNF-α, the phorbol ester
2-O-tetradecanoylphorbol-13-acetate (TPA), TGF-β and the
interleukin (IL)-2 [17, 18, 23–25]. On the other hand, IFN-β
as well as IFN-γ have been found to repress the production of
MMP-9 by T cells [17, 26, 27]. The NK and T cell activating
cytokine IL-2 can in T cells increase MMP-9 production and
MMP-dependent migration [14, 28]. Furthermore, increased
collagenolysis was evident when IL-2 stimulated T cells were
cultured with tumour cells but not in peripheral blood T cells
[28]. Also, IL-8 increases the expression of MMP-2 and
MMP-9 in human T cells as well as their migratory ability
[29]. Focal adhesion kinase (FAK) regulates integrin-
dependent MMP-2 and -9 expression and release by T cells
[30] and production of MMP-9 by T cells from tumour
bearing mice increases in parallel to tumour burden, possibly
via vascular endothelial growth factor (VEGF) [31].
Quantitative data on the secretion of MMPs are scarce but
human T cells were found to produce higher amounts of
MMP-2 and MMP-9 compared to NK cells [17]. However,
this vast screening report using semi-quantitative gelatine
zymography does not clearly adjust for difficulties ensuring
cell viability in the necessary culture procedure. In fact, NK
cells seem, from the current knowledge, to be better
equipped to efficiently degrade a wide range of ECM
structures due to the large variety of MMPs they express.
We have found that while most MMPs detected in freshly
isolated human NK cells are only moderately expressed,
MT6-MMP is expressed at a much higher level than the
other MMP members [6]. Most likely T- and NK cell
migration has many common features and they probably use,
at least partly, similar molecular machinery. Therefore, some
of the findings for T cells might also apply for NK cells and
vice versa. However, since no or only few direct comparing
data are available such a statement has to await those studies.
Localisation of MMPs
It has been assumed that MMPs are released immediately
following formation. However, pre-synthesized MT1-MMP
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network/endosomes of HT1080 fibrosarcoma cells awaiting
trafficking to the cell membrane [32] and neutrophils have
been shown to store MMP-8 and MMP-9 in granules that
are rapidly released upon activation [33].
Cell surface containment of proteolytically active MMPs
will optimize matrix degradation at the invasive front and,
interestingly, also soluble MMPs may localize to the cell
membrane. For instance, expression of membrane-bound
MMP-8 was found to be up-regulated during neutrophil
migration through Matrigel [34]. Furthermore, translocation
of MMP-8 and MMP-9 to the cell surface of activated
neutrophils was associated with an increased stability and a
resistance to inhibition by tissue inhibitors of metallopro-
teinases (TIMPs) [34, 35]. Moreover, MMP-2, -7 and -9
have been shown to re-localize to the surface of malignant
cells through association with proteoglycans, the
proteoglycan-binding membrane receptor CD44 and integ-
rin αvβ3[ 36–40]. Since activated cytotoxic lymphocytes
also express CD44 and αvβ3, it is fully possible that
temporal cell surface retention of activated MMP members
occurs in these cells via the same mechanism. Morpholog-
ical evidence of MMPs in NK cells by antibody staining
has proven very difficult, likely because of the low amounts
of MMPs, and we have found no solid evidence for a
granular storage of MMPs in NK cells despite extensive
studies based on light and electron microscopy. However,
by subcellular fractionation and subsequent gelatine
zymography, evidence of a membrane localization of
MMP-2 was obtained from the YT cell line [3].
Utility of MMPs
Matrix-degrading enzymes are known to be needed for the
ability of malignant cells to invade dense matrices and the
importance of MMPs in invasion has also been demon-
strated in non-malignant cells e.g. vascular smooth muscle
cells, keratinocytes, osteoclasts, macrophages and endothe-
lial cells, reviewed in [2, 41–43].
In vitro studies of freshly isolated NK cells from human,
mice and rats have shown that their migration through
Matrigel depends in part on MMPs. Inhibition of freshly
isolated human NK cell migration by the hydroxamate
MMP-inhibitor GM6001 is in the 30%–60% range [4, 6].
Studies on rodent NK cells have shown that inhibition of
MMPs using the MMP inhibitor batimastat (BB94) decreased
rat A-NK cell migration by 50% while mouse A-NK cell
migration was inhibited up to 70%–90% [7, 8]. The rat NK
cell line RNK-16 has also been used to study the role of
MMPs in NK cell migration and both GM6001 and BB94
inhibited their migration through Matrigel by approximately
50% [9, 44]. Likewise, invasion through Matrigel by T cells
(both freshly isolated and cell lines) is facilitated by MMPs,
since treatment with GM6001 or BB94 can reduce invasion
by 30%–70% [14, 23, 24, 45]. Migration of T cells may also
be reduced using selective gelatinase inhibitors in experi-
mental models of inflammation [29].
The above mentioned studies all show an incomplete
reduction of the migratory ability of both T- and NK cells
using MMP inhibitors. Similarly, it has been demonstrated
that cancer cells have an ability to traverse Matrigel despite
presence of GM6001 [46], and that a capacity to invade
Matrigel does not reflect invasive ability in vivo [47]. The
here tested MMP inhibitors are not equally effective in
inhibiting various MMPs and some might not be inhibited
at all despite the high molar excess used in vitro. These
findings could also be partly explained by the structural
difference of Matrigel compared to authentic BMs, with a
lower level of cross-linking, which consequently influences
the relevance of Matrigel as a model of native BM. And, as
later will be discussed, also other proteases and migration
strategies do likely operate as well.
Lymphocyte Locomotion in 3D Environment/Migratory
Strategies
Adhesion molecules have for long been considered a key
component in facilitating and mediating lymphocyte hom-
ing and migration [48]. However, helped by the emergence
of new and improved optical imaging technologies and the
ease of gene knockout, new insights in cell locomotion in
3-dimensional matrices has been obtained. Much of the
data has been obtained from dendritic cells acting as a
model of leukocytes. Based on these studies, it has become
clear that while attachment/adherence of lymphocytes to
ECM for migration in 2-dimensional environments involves
integrins, immune cells may well migrate in 3-dimensional
matrices both in vitro and in vivo without the need for focal
adhesion [49–52].
Lymphocyte migration in 3-dimensional matrices is now
being described as amoeboid, i.e. a migration mode
characterized by a rounded or ellipsoid cell shape with
instable non-focalized adhesion sites and lack of stress
fibres that allows the cells to migrate at high speed (10 μm/
min) and squeeze through narrow matrix gaps [53–55]. If
this is also the case in tumour tissue is yet to be shown, as
here rapid tumour growth will lead to a disorganized
morphology where possible normally present conductive
traits or cellular pathways may become obstructed by either
tightly packed tumour cells or an unstructured formation of
matrix products from the malignant cells. In rodent
experimental tumour models NK cells have been shown
to deform into extremely thin formations during extravasa-
tion and intra-tumour migration, ~3 μm, where the nucleus
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tissue might not leave such gaps and could thereby
physically resist lymphocyte invasion.
Less well documented, with only in vitro data using
cultured mouse A-NK cells and human NK cell lines, is the
possibility of a release of hydrophilic proteoglycan-
containing material with matrix-dilating properties as a
potential migratory strategy [58, 59]. Such tissue-loosening
effects have previously been demonstrated during mesen-
chymal cell migration and also to facilitate malignant cell
invasion [60–62]. Clearly, there are many different compo-
nents and several mechanisms involved in tissue migration,
which could very well be operating in different situations or
even simultaneously.
While the dependence of firm adhesion in 3-dimensional
migration may be low, it is of high importance for the initial
arrest in the microvessel and for extravasion across the
endothelial lining [63, 64]. Although inhibition of proteases
can cause a transition from protease-dependent migration to
the amoeboid-like movement that allows cells to squeeze
through narrow matrix gaps [65–67], the high density that
characterizes basement membranes and some connective
tissues makes it difficult to compensate matrix-degradation
with shape change [68]. Therefore, lymphocytes migrating
within tumour tissue, aiming at positioning themselves in
direct contact with malignant cells, must likely depend on
both matrix degradation and shape modulation.
Most lymphocyte-mediated killing mechanisms are
dependent on a close contact between the immune cell
and its target. It has however experimentally been shown
that many extravasated lymphocytes remain localized in the
stroma surrounding the tumour nests [57, 69–74]. This
could be part of the explanation for the limited efficiency
seen in adoptive immunotherapy [75]. Nevertheless, many
of the lymphocytes do manage to migrate in between
tumour cells and do establish close membrane contact with
these. Whether the migrating lymphocyte needs cell-cell or
cell-matrix interactions, or both, in order to receive the
signals needed to continue its movement, is unclear. Thus,
the extracellular matrix may thereby be seen as both a
barrier and an important component to ensure forward
propulsion. The arsenal of MMPs needed for an efficient
migration of lymphocytes will likely vary with the ECM
composition of the environment [76–78]. Thus, one could
hypothesise that some lymphocytes are functionally defi-
cient of the proteases needed to penetrate a specific tumour
environment (an inverse of the “seed and soil” hypothesis
proposed by Paget for the metastatic process [79]), which
could contribute to a limited lymphocyte invasion. Since
the exact preferred in vivo substrate for each MMP member
is still mainly unknown, this issue is inherently difficult to
study [80]. As to the question whether the presence of
extracellular matrix is needed to ensure forward propulsion,
we have observed significant migration of adoptively
transferred IL-2-activated lymphocytes (LAK cells) of both
T- and NK cell origin, into areas of tumours, which,
appeared to be composed solely of tumour cells, i.e., with
very little if any laminin, fibronectin and collagen [73]
(Fig. 1). While the average density of LAK cells was found
to be significantly higher in the ECM-rich tumours, ECM-
low tumours also contained significantly more LAK cells
than the surrounding normal lung tissue [73]. In the EMC-
low nodules, the density of LAK cells was higher in areas
close to ECM elements (e.g., at the edge of the tumour or
around blood vessels), but a substantial fraction of the LAK
cells was found at distances greater than 100 μm from the
nearest, detectable matrix components. Thus, the presence
of ECM may not be a prerequisite for the ability of
activated lymphocytes to infiltrate and move around in
solid tumours.
A number of studies have examined the ability of
various lymphocytes to migrate into tumour-derived sphe-
roids. For example IL-2 activated T- and NK cells have
been investigated for their capacity to migrate into the
intercellular space of a multicellular spheroid grown from a
human glioblastoma [81]. In this system, migration was
investigated via the use of different classes of inhibitors
which had effect on various adhesion systems including
cell-matrix or cell-cell interactions, e.g. α3β1 to fibronec-
tin, laminin and collagen, but no such in vitro studies
regarding proteases or protease inhibitors has been done.
Microenvironmental Regulatory Factors
Regulation of the MMPs occurs at several different levels,
transcriptionally through induced or repressed expression,
posttranscriptionally with proteolytic activation of the
zymogen form and inhibition of the active enzyme by
specific inhibitors. Also the extravasating lymphocyte may
encounter several regulatory factors in the tumour micro-
environment. Human NK cells infiltrating tumour nests
have a relatively suppressed immunophenotype in contrast
to the stromally located NK cells [82], which raises the
question of the possibility of various subsets of effector
cells. Further, there is an extensive cross-talk with other
immune cells that will affect the lymphocytes activation
status [83]. A number of reports have appeared that link the
activation of MMPs to oxidative stress. For example, MMP
inhibition has been suggested as a novel therapeutic
strategy for the prevention of oxidative stress related
damage to the heart [84]. In addition, high levels of oxygen
radicals produced by tumour associated macrophages can
suppress T- and NK cells cytotoxicity and viability [85]. A
low pH level, which is often found within tumour tissue,
has further been found to influence both lymphocytes
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large decrease in pH has negative effects on lymphocyte
activity, a slight decrease has been shown to increase IL-2-
activated T cells locomotion in in vitro ECM gels,
indicating a finely tuned balance, the latter was suggested
to be explained by an enhanced heparanase production [87].
Much has been written about the impact of a hypoxic
environment on cellular chemotaxis and migration [88].
Hypoxia has been shown to suppress monocyte–derived
dendritic cell MMP-9 [89]. In addition hypoxia has also
been reported in multiple cellular systems to reduce MMP
production. For instance, hypoxia has been found to reduce
the output of TNF-α-induced proMMP-9 by three fold in a
monocytic cell line and in primary human monocytes [90].
It has further been hypothesized that attachment of
proMMP-9 to cell membranes is increased after hypoxia,
consistent with its interactions with surface molecules such
as CD44. Moreover, the reduced migration of monocytes in
hypoxia was found to be mediated at least in part by
secreted MMP-9 suggesting that hypoxia posttranslation-
ally can reduce secreted amounts of proMMP-9 mostly by
cellular trafficking but also by attachment to the membrane
[90].
In vivo the extracellular source of active MMPs is
intriguing. As known, tumour cells use MMPs and other
matrix degrading proteases in their dissimination and in
various steps of the metastatic process. And in malignant
cell tissue invasion a substantial part of the matrix
Fig. 1 LAK cell infiltration of lung metastases with high and low
content of extracellular matrix components. Splenocytes from
Thy1.1+ C57BL/6 congenic mice were incubated with IL-2. After
5 days of incubation, the cells, containing approximately equal
amounts of NK cells, CD8+ T cells, and NKT cells, were
harvested. 5×10
6 LAK cells were injected i.v. into Thy1.2+
C 5 7 B L / 6m i c eb e a r i n g9d a y so l dM C A - 1 0 2p u l m o n a r ym e t a s t a s e s .
20,000 U Peg-IL-2 were given twice a day to support the injected
cells. At 72 h after injection, lungs were removed, fresh frozen and
cryosections were prepared. Sections were stained with PE-
conjugated anti-Thy1.1 antibody to reveal the LAK cells and with
FITC-conjugated anti-Laminin antibody to reveal laminin. Tumours
are outlined (white). a DIC (Differential interference contrast)
photomicrograph of lung tissue showing a larger metastasis, growing
around a vessel (asterisk), and a smaller, more pleomorphic
metastasis developing in the lung parenchyma with no relationship
to larger vessels. b The same area as shown in A after staining with
FITC-conjugated anti-laminin antibody. While the larger, perivas-
cular metastasis contains very little laminin, the smaller, pleomor-
phic metastasis is rich in laminin. c T h es a m ea r e aa ss h o w ni nA+B
after staining with PE-conjugated anti-Thy1.1 antibody. The density
of LAK cells in the laminin-low, perivascular metastasis is
substantially higher than in the surrounding normal lung tissue, but
not as high as the density of LAK cells in the laminin-rich metastasis
[73]. d Overlay of B and C: While the distribution of LAK cells in
the laminin-rich nodule is relatively homogenous, the density of
LAK cells is higher near laminin-dense areas of the laminin-low
nodule. However, many LAK cells (arrow-heads) in the laminin-low
nodule have migrated away from the laminin-rich edges and into
what seems to be laminin-free areas. Bars=200 μm
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stroma cells [91]. Similarly, T cell interaction with
endothelial cells leads to MMP-2 activation, induced
expression of MMP-9 and increased MMP-1 and MMP-3
expression in endothelial cells [92]. It has furthermore been
shown that T cells induce MMP-1 [93] and MMP-9 [94]
expression in monocytes and fibroblasts during co-culture.
EMMPRIN/CD147 is a cell surface protein with extracel-
lular metalloproteinase inducer activity. It is highly
expressed in tumour cells and promotes MMP production
by stromal cells. EMMPRIN/CD147 has been described to
be expressed by human peripheral T cells [95, 96],
however, the detailed function of EMMPRIN in invasion
is still not well studied.
Other Matrix-Degrading Enzymes
Besides MMPs, the urokinase plasminogen activator (uPA)
system is also implicated in ECM degradation and BM
passage by lymphocytes [1, 2]. The uPA system with uPA
and its receptor uPAR contributes to ECM degradation by
converting plasminogen into active plasmin, which
degrades multiple matrix proteins and can also activate
MMPs through proteolytic processing [97].
Extracellular and cell-associated plasminogen activators
were first reported to be produced by highly purified NK
cells with molecular characteristics including those of uPA
suggesting a role for the uPA system in several aspects of
NK cell function [98, 99]. Through inhibition studies the
uPA/uPAR system has been shown to be involved in rat NK
cell migration, and there are evidence for a cooperation of
the uPA system and MMPs in NK cell migration [44]. The
uPA-uPAR system has further been showed to be involved
in T cell invasion [100–102], indicating the importance of
the uPA system in lymphocyte invasion. It has been
suggested that uPAR is a signalling receptor and regulator
of integrins in NK cells with impact on NK cell function
[103]. Moreover, co-capping and fluorescence microscopy
have shown that uPAR physically associates with the αν
integrin on the surface of NK cells of the YTcell line [104].
This has suggested that signalling initiated by uPAR
binding to uPA or by uPAR clustering may be dependent
upon the physical association of uPAR with integrins.
Among other potential matrix degrading enzymes are the
endoglycosidase heparanase. Heparanase is mostly pro-
duced by tumour cells, but also by lymphocytes [105] and a
co-regulation between heparanase and MMP expression has
been demonstrated [106, 107]. Of potential interest to study
with references to the malignant cell invasion counterpart
are seprase and elastase. While seprase isa membranebound
serine protease with gelatinase activity over expressed in
malignant cells and found to associate with MMPs on the cell
surface of tumour cells [108], elastase is a serine protease
produced also by T cells [109].
The co-stimulatory antigen CD26, identical to the serine
dipeptidylpeptidase IV, is induced on cytokine stimulated
NK cells [110] and it has been proposed to participate in
matrix degradation. Furthermore, the papain family of
cystein peptidases cathepsin B, H, L, S and the aspartic
cathepsin D, have been implicated in malignant behaviour
contributing to matrix breakdown [111, 112]a n dt h e
tetramer of related enzymatic subunits, dipeptidylpeptidase
I (DPPI), is further found in the granules of cytotoxic
lymphocytes [113], and has been implicated in degradation
of matrix components [114].
Of particular interest, due to its relative abundance, is
that the granular stored serine protease granzyme B, which
is part of the extensive cytotoxic machinery in cytotoxic
lymphocytes, has also been reported to degrade both non-
collagenous and ECM-associated components including
laminin, fibronectin, vitronectin and aggrecan proteoglycan
[115, 116]. While it is well recognized that the uPA system
can degrade laminin and fibronectin as well as activate
some latent pro-forms of MMPs, granzymes too might
function in concert with lymphocyte MMPs to degrade the
key ECM and BM components laminin and type IV
collagen.
Immunmodulating Effects of MMPs
It has increasingly been recognized that the proteolytic
action of MMPs is not restricted to only degradation of
ECM components and that MMP therefore can be given an
immunomodulating role. MMPs have been shown to
selectively degrade non-matrix substrates including chemo-
kines and cytokines and thereby contribute to cellular
migration via multiple pathways [117]. Moreover, MMPs
have now been found to be implicated in selective
proteolysis of cell surface substrates, including integrins,
growth factors and receptors [118]. Such selective proteol-
ysis of non-matrix substrates, as well as ECM components,
modulates many processes including tumour progression,
cell survival and cell proliferation [1, 119, 120]. Impor-
tantly, the ECM may serve as a reservoir for growth factors
and cytokines controlling their availability and activity. The
highly important cytokine IL-2, has for example been
shown to bind to collagen [121], and when released after
collagenolytic activity it can provide a temporal important
stimulation to the migrating T- or NK cells.
There are several mechanisms by which MMP-9 functions
asa modulator toregulatethe immuneresponse.For example,
MMP-9 can cleave and activate the cytokine IL-1, which
induces the expression of MMP-9 in several cell types; it
potentiates the effect of IL-8 through truncation and can also
356 K. Edsparr et al.cleave and inactivate the IL-2 receptor α chain [122]. Also,
proteolytic processing of pro-TNF-α by MMP releases
soluble TNF-α from the cell surface of peripheral blood
mononuclear cells (PBMCs) [123].
Future Perspectives
This article reviews the pleiotropic functions of
lymphocyte-derived MMPs in a number of killer cell
functions. This includes but may not be limited to issues
of cellular migration and localization of effector cells
within the microenvironment of tumour metastases. In
recent years quantitative peptidic-centric proteomic tech-
nologies, including those that recover N-terminal pep-
tides have supplemented biochemical and genetic
approaches for the identification of protease substrates;
these have helped identify natural protease substrates
while identifying their selective cleavage sites in com-
plex backgrounds of thousands of distinct proteins [124].
As proteolytic processing receives increasing attention in
the studies of signalling pathways as well as in cellular
differentiation, protease substrates have also been sought
via shotgun as well as mass spectrometry-driven substrate
degradomics [125]. It has thus become increasingly clear
that proteolysis mediated by MMPs and other lymphocyte-
derived proteolytic enzymes are not limited to only the
degradation of ECM substrates but can also be extended to
a broader regulatory role via proteolysis of an array of
additional physiological substrates. It is thus to be
anticipated that future studies, for the identification of
multiple substrates for proteolytic enzymes, will further
illuminate the role for lymphocyte-derived proteases in
numerous additional regulatory functions for these
enzymes at both the cellular and molecular levels.
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